QUA has launched the FEDI-2Rx Fractional Electrodeionization product range.
QUA® says that the FEDI® is specially designed for applications in pharmaceutical, biomedical and laboratory applications where installations require hot water sanitisation to meet pharmacopoeia standards for Purified Water (PW) and Water For Injection (WFI).
"After successful acceptance of our industrial range of FEDI, we are now ready to service the pharma, medical, biomedical, cosmetics and laboratory arena with our product range branded as FED-2 Rx. We are confident that our patented process of manufacturing ion exchange media will provide improved reliability of performance in these applications," said V J Nathan, Technical Director, QUA Group.
In a short span of two years, the QUA Group's FEDI has more than 25 global installations including various sites in USA, Europe and Asia. The company recently received the 2013 Frost & Sullivan New Product Innovation Award for Industrial Water & Wastewater Treatment Technology, North America, for FEDI Electrodeionization and its Q-SEP® Hollow Fiber Ultrafiltration Modules.
With patented dual voltage technology, QUA's FEDI technology is the next generation of electrodeionization (EDI) technology for the production of high purity water. Developed taking into account the limitations of conventional EDI, the FEDI process improves the reliability of EDI for the production of high purity water.
